Q1 2027 Marksans Pharma Ltd Earnings Call Transcript
Key Points
- Record quarterly revenue of INR 841 crore, up 35.6% year-on-year, with highest-ever EBITDA of INR 213 crore and PAT of INR 159 crore.
- Strong growth in U.K. and Europe, with revenue up 74.7% year-on-year, driven by acquisitions and organic expansion.
- Gross margin expanded to 59.1%, up 138 basis points year-on-year, supported by favorable product mix and lower-cost inventory.
- Cash balance crossed INR 1,000 crore for the first time, with net cash at INR 1,031 crore, despite acquisition payments.
- Working capital cycle improved to 132 days from 159 days in the prior year, enhancing operational efficiency.
- Management reaffirmed target of INR 4,000 crore revenue within two years, with growth expected across all geographies.
- Successful integration of QliniQ B.V. and ABCnow GmbH, with plans to expand further in Europe, targeting EUR 180 million in revenue for FY 2027.
- Gross margin is expected to normalize to 55-56% as low-cost inventory is depleted and geopolitical pressures on raw material costs persist.
- North America saw softer demand during the summer months, with price erosion in the Rx portfolio remaining in single digits.
- Rest of world markets are struggling due to geopolitical tensions and transportation hurdles, impacting growth in those regions.
- Management maintained conservative guidance of 15-20% revenue growth and 20-21% EBITDA margin, citing geopolitical volatility.
- R&D spend increased to 2.8% of revenue, up from 2% in the prior year, reflecting higher investment in product development.
- The company is not actively pursuing backward integration or CRAMS, which could limit long-term cost advantages.
- Potential U.S. tariff threats (e.g., 200% duty) remain a risk, though management views this as uncertain and long-term.
Ladies and gentlemen, good day and welcome to Marksans Pharma Q1 FY 2027 earnings conference call hosted by DAM Capital Advisors Limited. (Operator Instructions) I now hand the conference over to Mr. Nitin Agarwal. Thank you, and over to you, sir.
Welcome to Marks and Pharma's Q1 F27 Post Results Earnings Call hosted by DAM Capital Advisors Limited. On the call today, we have representing Demarks and Pharma, Mr. Mark Saldana, Founder and Chairman and Managing Director and Mr. Jitendra Sharma, Chief Financial Officer. I'll hand over the call to Mark to make the opening comments and then we'll open the floor for questions from there on.
Thank you, Nitin. Good afternoon, everyone, and thank you for joining us for our Q1 FY 2027 earning conference call. We sincerely appreciate your interest and continued support for the company. Q1 FY 2027 has been a very strong start to the year for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
